The purpose of the study is to find out which medicine better prevents low blood pressure (hypotension) while the patient is being treated before hospital admission. Participants who need pre‑hospital sedation and ventilation are randomly given either the test drug or the comparator drug. Their blood pressure and oxygen levels are monitored from the first reading in the ambulance until they leave the trauma centre, and their recovery is checked again about six months later.

During the observation period the study records any episodes of very low or very high blood pressure, as well as low oxygen levels, and later evaluates how well patients can perform everyday activities using standard rating scales that measure functional ability. No additional procedures beyond the emergency care needed for the injury are performed as part of the study.

The purpose of the study is to determine whether giving the drug in the 4.5‑ to 24‑hour window after the stroke improves recovery compared with a placebo. Participants will be randomly assigned to receive either the medication or the placebo, and will undergo brain imaging with CT or MRI to confirm that there is still brain tissue that can be saved. Recovery will be measured at 90 days using the modified Rankin Scale, a simple questionnaire that rates how well a person can perform everyday activities.

After enrollment, the study drug is administered intravenously, and the patient is transferred to a specialized center for the possible endovascular procedure. Follow‑up includes additional brain scans to check for bleeding, phone interviews to assess daily function, and a final health evaluation at three months. All assessments are performed by staff who do not know which treatment the participant received.

The purpose of the study is to evaluate whether the medication can reduce excessive daytime sleepiness in people with the condition. Participants are randomly assigned to receive either the active drug or the placebo during a double‑blind phase, meaning neither the participants nor the study staff know which treatment is being taken. After this period, all participants may enter an open‑label extension where everyone receives the active medication, with regular visits to monitor safety and symptom changes over several months.

Participants will be randomly assigned to receive either the study drug or placebo for up to twelve weeks, with regular clinic visits to evaluate changes. Anxiety severity will be measured using the HAM-A questionnaire, a list of questions that rates how intense anxiety symptoms are. Overall clinical improvement will be recorded with the CGI scale, where a clinician judges how much the condition has changed. Patients will also provide their own view of improvement on the PGI-I scale, a simple rating of how they feel compared with the start of treatment. General well‑being will be assessed with the WHO-5 questionnaire, which asks about mood and daily life satisfaction.

Safety will be closely observed throughout the study, with any side effects such as liver problems or skin reactions being reported promptly. The trial follows a double‑blind design, meaning neither the participants nor the investigators know which treatment is being given, to ensure unbiased results.

The purpose of the study is to evaluate the effectiveness and safety of adding Privosegtor to standard therapy for individuals with Optic Neuritis.

Participants receive the infusion at the start of the study and are followed for three months, with clinic visits to check vision and safety. Vision is tested using low contrast visual acuity, a measure of how well a person can see faint patterns, and the eye’s structure is examined with optical coherence tomography, a non‑invasive scan that measures retinal layer thickness. A blood test for serum neurofilament light chain is performed to assess nerve damage, and questionnaires evaluate the impact of vision changes on daily life. Changes in these assessments are compared between the drug and placebo groups.

The purpose of the study is to assess how safe and well‑tolerated the new medication is when added to current therapy. The design is double‑blind, meaning that neither the participants nor the study staff know which capsule contains the active drug, and it is used as adjunctive therapy, meaning it is given in addition to the medicines participants are already taking.

After an initial screening visit, eligible individuals are randomly assigned to receive either the study drug or the inactive pill for several weeks, with regular clinic visits to check vital signs, heart rhythm, laboratory tests, and any side effects. At the end of the treatment period, participants have a final visit to review overall health and to discontinue the study medication under medical supervision.

The purpose of the study is to evaluate the safety and effectiveness of SAR448851 in people with early Alzheimer’s disease. Participants will take the study medication every day for about 48 weeks, during which they will have regular visits for simple blood tests that measure a protein called p‑tau217, a marker that can show changes related to the disease, and may also undergo a brain scan to look for amyloid plaques, which are tiny buildups associated with Alzheimer’s. After the first 48 weeks, participants may choose to continue in an open‑label phase, where everyone receives the active medication, for up to another year, with continued monitoring.

Throughout the trial, safety is closely watched by checking for any side effects, measuring vital signs, and performing routine laboratory tests. Any serious problems are recorded, and participants can stop the study at any time if needed.

The aim of the study is to determine whether the drug can improve walking capacity in this population. Participants are randomly assigned to receive either the active tablet or the placebo for a defined period, with regular clinic visits for safety checks, blood pressure and heart rate monitoring, and simple questionnaires about mood and pain. At the start and at the end of the treatment period, each participant performs a six-minute walking test, in which the distance walked in six minutes is recorded.

Safety is assessed by recording any unwanted effects, checking basic blood work, and performing an electrocardiogram (ECG), a quick test that records the heart’s electrical activity. Functional outcomes include the walking distance, speed measured over a short distance, and self‑reported fatigue and quality of life. The study also tracks the number of falls and overall activity level to provide a broader picture of daily function.

Two medicines are being compared: an intravenous infusion of rituximab, which is given through a vein to target immune cells, and oral tablets of azathioprine, a pill that also reduces immune activity. Participants will receive the assigned medication over a period of up to two years while doctors monitor their health.

During the study, participants will have regular clinic visits, blood tests, and brain scans using MRI with contrast dye to check for any new or worsening signs of disease. The study will track how long participants stay free of relapse and record any side effects or changes in medication over the 24‑month follow‑up.

Participants are randomly assigned to receive either the study drug at two possible doses or the placebo, and neither the participants nor the study staff know which treatment is given. Over 52 weeks, participants attend regular clinic visits where safety is checked through physical exams, vital signs, weight measurements, and questionnaires about mood. Cognitive and functional abilities are measured using the clinical dementia rating – sum of boxes, a score that reflects the severity of dementia, and the integrated Alzheimer’s disease rating scale, a test that looks at memory and daily tasks. Blood samples are taken to assess proteins linked to Alzheimer’s, such as p-Tau217 (a form of tau protein), amyloid β-protein Aβ40 and Aβ42 (building blocks of plaque), as well as markers of nerve damage (neurofilament light chain) and brain inflammation (glial fibrillary acidic protein). Brain imaging includes a size‑measuring scan called volumetric magnetic resonance imaging and a special scan that visualizes amyloid plaques known as amyloid positron emission tomography. All data are collected to evaluate whether the medication is safe and whether it helps preserve thinking and daily abilities.

The purpose of the study is to evaluate whether Rimonabant can improve functional independence, meaning the ability to perform everyday activities without assistance. Throughout the trial, researchers will monitor safety by checking for any side effects, changes in vital signs, and overall well‑being. Functional ability will be assessed using simple tools such as the Barthel Index, which measures how well a person can manage basic tasks like dressing, eating, and moving around, as well as other straightforward tests of walking and balance. The study does not involve any experimental procedures beyond taking the study tablets and attending the scheduled check‑ups.